Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 2/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 6/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517356 | 0.80 | PTPN2 (0.40) | PTPN2BTN3A1EPHX2PPARGKDM4E | |
| SCHEMBL5507203 | 0.70 | PTPN1 (0.33) | PTPN2 | |
| SCHEMBL5507197 | 0.68 | PTPN1 (0.33) | — | |
| SCHEMBL27494852 | 0.66 | MGAM (0.39) | BTN3A1ALDH1A1HSD17B10FBP1 | |
| SCHEMBL12746431 | 0.65 | BTN3A1 (0.39) | BTN3A1ALDH1A1MMP8FBP1 | |
| SCHEMBL22837347 | 0.63 | POLB (0.50) | BTN3A1KDM4EPOLBALDH1A1TSHR | |
| SCHEMBL20181544 | 0.63 | MGAM (0.39) | BTN3A1ALDH1A1HSD17B10FBP1 | |
| SCHEMBL28273778 | 0.63 | MGAM (0.39) | BTN3A1ALDH1A1HSD17B10FBP1 | |
| SCHEMBL26524316 | 0.63 | BTN3A1 (0.54) | BTN3A1KDM4EPOLBMAPTHSD17B10 | |
| SCHEMBL26558610 | 0.62 | BTN3A1 (0.58) | BTN3A1KDM4EPOLBALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | PTPRO, PTPRG, PTPN1 | PTPN2 24/4885BTN3A1 753/4885EPHX2 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.